KR20240042640A - Erbb 및 btk 억제제의 신규한 약제학적 염 및 다형체 형태 - Google Patents
Erbb 및 btk 억제제의 신규한 약제학적 염 및 다형체 형태 Download PDFInfo
- Publication number
- KR20240042640A KR20240042640A KR1020247007187A KR20247007187A KR20240042640A KR 20240042640 A KR20240042640 A KR 20240042640A KR 1020247007187 A KR1020247007187 A KR 1020247007187A KR 20247007187 A KR20247007187 A KR 20247007187A KR 20240042640 A KR20240042640 A KR 20240042640A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- egfr
- crystal form
- xrpd pattern
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021110048 | 2021-08-02 | ||
| CNPCT/CN2021/110048 | 2021-08-02 | ||
| PCT/CN2022/109065 WO2023011358A1 (en) | 2021-08-02 | 2022-07-29 | Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240042640A true KR20240042640A (ko) | 2024-04-02 |
Family
ID=85154265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007187A Pending KR20240042640A (ko) | 2021-08-02 | 2022-07-29 | Erbb 및 btk 억제제의 신규한 약제학적 염 및 다형체 형태 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250197377A1 (https=) |
| EP (1) | EP4380924A4 (https=) |
| JP (1) | JP2024529533A (https=) |
| KR (1) | KR20240042640A (https=) |
| CN (1) | CN117794902A (https=) |
| AR (1) | AR126673A1 (https=) |
| AU (1) | AU2022324410A1 (https=) |
| CA (1) | CA3224748A1 (https=) |
| MX (1) | MX2024001367A (https=) |
| TW (1) | TW202321223A (https=) |
| WO (1) | WO2023011358A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4731307A1 (en) | 2023-06-23 | 2026-04-29 | Assia Chemical Industries Ltd. | Solid state forms of sunvozertinib |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014022790B1 (pt) * | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo |
| CN105384694B (zh) * | 2014-08-22 | 2020-09-04 | 四川海思科制药有限公司 | 一种取代的氨基嘧啶衍生物及其制备方法和药物用途 |
| CN106905245B (zh) * | 2015-12-23 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 2,4-二取代的嘧啶类化合物 |
| CN106083736A (zh) * | 2016-06-21 | 2016-11-09 | 郑州泰基鸿诺医药股份有限公司 | 一种嘧啶类化合物、egfr抑制剂及其应用 |
| TWI798334B (zh) * | 2018-01-31 | 2023-04-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Erbb/btk抑制劑 |
| WO2019177375A1 (ko) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2022
- 2022-07-29 CA CA3224748A patent/CA3224748A1/en active Pending
- 2022-07-29 KR KR1020247007187A patent/KR20240042640A/ko active Pending
- 2022-07-29 JP JP2024506641A patent/JP2024529533A/ja active Pending
- 2022-07-29 US US18/293,778 patent/US20250197377A1/en active Pending
- 2022-07-29 MX MX2024001367A patent/MX2024001367A/es unknown
- 2022-07-29 AU AU2022324410A patent/AU2022324410A1/en active Pending
- 2022-07-29 TW TW111128540A patent/TW202321223A/zh unknown
- 2022-07-29 CN CN202280053629.5A patent/CN117794902A/zh active Pending
- 2022-07-29 EP EP22852071.4A patent/EP4380924A4/en active Pending
- 2022-07-29 WO PCT/CN2022/109065 patent/WO2023011358A1/en not_active Ceased
- 2022-08-02 AR ARP220102058A patent/AR126673A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023011358A1 (en) | 2023-02-09 |
| US20250197377A1 (en) | 2025-06-19 |
| CN117794902A (zh) | 2024-03-29 |
| EP4380924A4 (en) | 2025-10-01 |
| MX2024001367A (es) | 2024-02-27 |
| JP2024529533A (ja) | 2024-08-06 |
| CA3224748A1 (en) | 2023-02-09 |
| TW202321223A (zh) | 2023-06-01 |
| AR126673A1 (es) | 2023-11-01 |
| EP4380924A1 (en) | 2024-06-12 |
| AU2022324410A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017282903B2 (en) | Crystals of aniline pyrimidine compound serving as EGFR inhibitor | |
| TW202110836A (zh) | 固態形式 | |
| TW202519524A (zh) | 固態形式 | |
| CN115803330B (zh) | 4-氨基-5-(6-(4-甲基哌嗪-1-基)-1H-苯并[d]咪唑-2-基)噻吩并[2,3-b]吡啶-6(7H)-酮的盐和晶型 | |
| KR20180021743A (ko) | 프테리디논 유도체인 표피 생장 인자 수용체 억제제의 응용 | |
| AU2013245878A1 (en) | Salt form of a human histone methyltransferase EZH2 inhibitor | |
| EP4234547A2 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| KR100687165B1 (ko) | 결정성 2,5-디온-3-(1-메틸-1h-인돌-3-일)-4-[1-[1-(피리딘-2-일메틸)피페리딘-4-일]-1h-인돌-3-일]-1h-피롤 모노-하이드로클로라이드 | |
| KR20240042640A (ko) | Erbb 및 btk 억제제의 신규한 약제학적 염 및 다형체 형태 | |
| TW202311267A (zh) | 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用 | |
| HK40109564A (zh) | Erbb和btk抑制剂的新型药用盐和多晶型形式 | |
| KR20250170660A (ko) | 퀴나졸린 erbb 억제제의 약학적 형태 | |
| TWI920085B (zh) | 4-胺基-5-(6-(4-甲基哌-1-基)-1h-苯并[d]咪唑-2-基)噻吩并[2,3-b]吡啶-6(7h)-酮之鹽及晶形 | |
| TW202342041A (zh) | 一種藥物組合物及所含活性成分化合物的製備方法 | |
| HK40126640A (zh) | 喹唑啉erbb抑制剂的药物形式 | |
| WO2023230968A1 (zh) | Shp2抑制剂、其晶型及其制备方法与用途 | |
| KR20210050530A (ko) | 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도 | |
| HK40096550A (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| HK40042843A (en) | Salt form and crystal form of novel azatricyclic compound and use thereof | |
| HK40072166B (zh) | 杂环化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |